The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 172, Issue 12, 2005, Pages 1487-1490

  Gelperina, Svetlana ^b   Kisich, Kevin ^b   Iseman, Michael D ^b   Heifets, Leonid ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b NONE

Author keywords

Antituberculosis drugs; Nanoparticles; Tuberculosis therapy

Indexed keywords

CLOFAZIMINE; DRUG CARRIER; ISONIAZID; NANOPARTICLE; POLYGLACTIN; PYRAZINAMIDE; RIFAMPICIN;

CHEMOTHERAPY; CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; DRUG TISSUE LEVEL; EPIDEMIC; FEASIBILITY STUDY; HYDROPHILICITY; HYDROPHOBICITY; NANOTECHNOLOGY; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NANOSTRUCTURES; TUBERCULOSIS;

EID: 30444441465     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200504-613PP     Document Type: Review

References (32)

1. Salem II, Flasher DL, Duzgunes N. Liposome-encapsulated antibiotics. Methods Enzymol 2005;391:261-291.
2. Khuller GK, Kapur M, Sharma S. Liposome technology for drug delivery against mycobacterial infections. Curr Pharm Des 2004;10:3263-3274.
3. Kreuter J. Nanoparticles as drug delivery system. In: Nalwa HS, editor. Encyclopedia of nanoscience and nanotechnology. Vol. 7. New York: American Scientific Publishers; 2004. pp. 161-180.
4. Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 2004;21:387-422.
5. Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev 2003;55:519-548.
6. Couvreur P, Barratt G, Fattal E, Legrand P, Vauthier C. Nanocapsule technology: a review. Crit Rev Ther Drug Carrier Syst 2002;19:99-134.
7. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70:1-20.
8. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257-1272.
9. Florence AT. Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target 2004;12:65-70.
10. Bummer PM. Physical chemical considerations of lipid-based oral drug delivery: solid lipid nanoparticles. Crit Rev Ther Drug Carrier Syst 2004;21:1-20.
11. Florence AT, Hussain N. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. AdvDrug Deliv Rev 2001;50:S69-S89.
12. Pandey R, Zahoor A, Sharma S, Khuller GK. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edinb) 2003;83:373-378.
13. Sharma A, Pandey R, Sharma S, Khuller GK. Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int J Antimicrob Agents 2004;24:599-604.
14. Ain Q, Sharma S, Garg SK, Khuller GK. Role of poly [DL-lactideco- glycolide] in development of a sustained oral delivery system for antitubercular drug(s). Int J Pharm 2002;239:37-46.
15. Dutt M, Khuller GK. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in poly (DL-lactide-co-glycolide) microparticles. J Antimicrob Chemother 2001;47:829-835.
16. Gabor F, Bogner E, Weissenboeck A, Wirth M. The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. Adv Drug Deliv Rev 2004;56:459-480.
17. Sharma A, Sharma S, Khuller GK. Lectin-functionalized poly (lactideco-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother 2004;54:761-766.
18. Pandey R, Khuller GK. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother 2005;55:430-435.
19. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003;52:981-986.
20. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) 2005;85:227-234.
21. Pinto-Alphandary H, Andremont A, Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int J Antimicrob Agents 2000;13:155-168.
22. Kayser O, Olbrich C, Croft SL, Kiderlen AF. Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs. Parasitol Res 2003;90:S63-S70.
23. Anisimova YV, Gelperina SE, Peloquin CA, Heifets LB. Nanoparticles as antituberculosis drugs carriers: effect on activity against M. tuberculosis in human monocyte-derived macrophages. J Nanoparticle Res. 2000;2:165-171.
24. Fawaz F, Bonini F, Maugein J, Lagueny AM. Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: pharmacokinetics and in vitro anti-microbial activity. Int J Pharm 1998;168:255-259.
25. Barrow ELW, Winchester GA, Jay K, Staas JK, Quenelle DC, Barrow WW. Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob Agents Chemother 1998;42:2682-2689.
26. Peters K, Leitzke S, Diederichs JE, Borner K, Hahn H, Muller RH, Ehlers S. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother 2000;45:77-83.
27. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004;3:785-796.
28. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53:283-318.
29. Pandey R, Khuller GK. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. J Antimicrob Chemother 2004;54:266-268.
30. Schmidt C, Bodmeier R. Incorporation of polymeric nanoparticles into solid dosage forms. J Control Release 1999;57:115-125.
31. Sham JO, Zhang Y, Finlay WH, Roa WH, Lobenberg R. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm 2004;269:457-467.
32. Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci USA 2002;99:12001-12005.